Malaria and iron deficiency cause a significant burden of disease in Africa. Iron deficiency (ID) might affect immune responses to vaccination.
In this double-blind randomized controlled trial, we aim to assess: (1) whether ID impairs R21/Matrix-M and measles (MR) vaccine response, (2) whether iron treatment at time of vaccination improves vaccine response.
Subject's caregiver is willing and able to give informed consent
Male or Female, 6 months (+/- 2 weeks) of age
Mother at least ≥15 years of age
Iron deficient (erythrocyte zinc protoporphyrin (ZnPP) >61 μmol/mol heme)
Severely anemic (Hb <70 g/L)
Malaria vaccination prior to enrollment
Medical condition that precludes study involvement
Iron supplementation 2 weeks before enrollment
Nicole Stoffel
Lead sponsor
ETH Zurich
Sponsor institution
Jomo Kenyatta University of Agriculture and Technology
Collaborator
University of Oxford - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
Collaborator
Faculty of Medical Sciences, Radboud University of Medical Center
Collaborator
National Institute for Public Health and the Environment (RIVM)
Collaborator